✨ Free AI Report
Neuphoria Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Neuphoria Therapeutics Inc.
Company Research

Neuphoria Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (...

Analyst-debate audio for Neuphoria Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for Neuphoria Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Early-stage biotech facing critical clinical trial failures with uncertain pathway forward despite Merck collaboration and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-Stage Drug Development
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Neuphoria Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Neuphoria Therapeutics Inc. Overview

Pro stress-test →

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024.

Strategic Profile

Pro stress-test →

Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions.

Competitive Landscape

Pro stress-test →

Neuphoria competes in the CNS therapeutics space against larger pharma developing anxiety and psychiatric disorder treatments. The company's focus on ion channel modulators for neuropsychiatric indications positions it in a specialized market segment with competitors pursuing similar or adjacent mechanisms.

Industry Context

Neuphoria Therapeutics Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development.

Key facts

Founded: 1996 · Headquarters: Burlington, Massachusetts · Market cap: $23.4M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Neuphoria Therapeutics Inc..

  • AFFIRM-1 Phase 3 trial failure for BNC210 in SAD; company will discontinue the SAD program and evaluate BNC210 for PTSD instead
  • Partnership with Merck offers up to $450 million of potential milestone payments plus royalties
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025AFFIRM-1 Phase 3 trial of BNC210 for social anxiety disorder failed to meet primary endpoints
  • October 2025Initiated strategic review of portfolio and operations with H.C. Wainwright as financial advisor
  • +1 moreTrack every material event for Neuphoria Therapeutics Inc. as it happens. Explore monitoring →
Get alerted when Neuphoria Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CNS Disorder TherapeuticsCollaborative partner on a7 receptor modulators for Alzheimer's→Psychiatric Disorder TreatmentsClinical-stage biotech focused on psychiatric disorders→

Compare Neuphoria Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Neuphoria Therapeutics Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about Neuphoria Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Neuphoria Therapeutics Inc. and its top competitor on Cyborg Score”
“What did Neuphoria Therapeutics Inc. do this quarter?”
“Is Neuphoria Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Neuphoria Therapeutics Inc. do?+
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (...
What is Neuphoria Therapeutics Inc.'s Cyborg Score?+
Neuphoria Therapeutics Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Neuphoria Therapeutics Inc.'s main competitors?+
Named competitors include CNS Disorder Therapeutics, Psychiatric Disorder Treatments. The full competitive landscape is in the AskCyborg report.
How can I get the full Neuphoria Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Neuphoria Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Neuphoria Therapeutics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score